June 15, 2021 Uncategorized

Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio

Data for EVRYSDI reinforce safety profile and efficacy in a broad spinal muscular atrophy (SMA) population, following recent EU approval Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) build on safety profile and efficacy following recent CHMP opinion, including in adults with concomitant autoimmune diseases (CAIDs) OCREVUS data continue to show consistent benefit on... Read more

May 25, 2021 Uncategorized

24 Hours of Life Science Conference

On June 2, 2021, JEOL will focus on advances in life science research using electron microscopy in its “24 Hours of Life Science” conference. Twenty-four different sessions throughout the full day will cover topics including: – Connectomics and the study of complete volumes of tissues or materials captured at high resolution– Correlative microscopy using light... Read more

May 12, 2021 Uncategorized

MKS Instruments Increases Quarterly Cash Dividend

ANDOVER, Mass., May 12, 2021 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, a ten percent Read more

May 6, 2021 Uncategorized

GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients

GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S.... Read more

May 5, 2021 Uncategorized

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU Basel, 5 May... Read more

April 23, 2021 Uncategorized

CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)

If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU ENSPRYNG is the only subcutaneous treatment option for NMOSD that can be administered at home every four weeks Recommendation is based on results from the... Read more